Pinealon is a synthetic tripeptide from the same Russian programme as Epitalon. It is investigated for how nerve cells cope with oxidative stress, in cell culture and rodent models.
Pinealon · Synthetic neuroactive tripeptide
Nerve cells are vulnerable to oxidative stress, the situation in which reactive molecules outpace the systems that keep them under control. Researchers want to know whether very short peptides can change how cells respond to that stress, and if so, how. Pinealon is one of the peptides used to ask that question. Nearly all the evidence comes from cell and rat studies published by one group of affiliated laboratories.
Pinealon is a synthetic tripeptide, glutamate-aspartate-arginine, written Glu-Asp-Arg or EDR. It was developed at the St Petersburg Institute of Bioregulation and Gerontology, which classifies it within a family of short 'peptide bioregulators' that also includes Epitalon. The programme's own description of Pinealon as a peptide for neural tissue is a research classification, not evidence that the molecule targets or accumulates in the brain.
The proposed mechanism is unusual. Conventional peptides act at receptors on the cell surface. The programme proposes instead that peptides this short pass into the nucleus and bind DNA directly, altering which genes are read. The support for that is computational: docking models that predict where short peptides could sit on DNA. Direct binding in living cells has not been demonstrated, so the DNA and gene-regulation account should be read as a hypothesis. What has been measured is downstream: less accumulation of reactive oxygen species and fewer dying cells in stressed cultures.
Cell culture. Khavinson et al. (2011) exposed rat cerebellar granule cells, neutrophils and PC12 cells to oxidative stress and reported that Pinealon reduced reactive oxygen species accumulation and necrotic cell death in a concentration-dependent way, with changes in ERK1/2 signalling and the cell cycle at higher concentrations.
Rats. Arutjunyan et al. (2012) fed pregnant rats a methionine load to raise homocysteine, a condition that harms the developing brain, and gave some of them Pinealon. Offspring of treated mothers performed better in spatial learning tests and their cerebellar neurons accumulated fewer reactive oxygen species. Earlier Russian-language work from the same group examined behaviour in aged rats under hypoxia.
Mice. Khavinson et al. (2021) used the 5xFAD mouse model of Alzheimer's disease and reported that the EDR peptide, with a related tripeptide, prevented loss of dendritic spines, the small protrusions on nerve cells where connections form; the mechanistic section of that paper again rests on DNA docking models.
This note did not identify a controlled human trial of Pinealon.
Everything above is preclinical: studied in cells or animals, not proof of the same result in people. The primary literature is small and comes almost entirely from affiliated laboratories, and independent replication is lacking. The DNA-binding mechanism is modelled rather than observed, and the antioxidant readouts could arise through other routes. How a three-residue peptide survives in the bloodstream and whether it reaches the brain after systemic administration has not been characterised in published pharmacokinetic work.
Pinealon is not an approved medicine in Australia. No regulator-approved Pinealon medicine was identified in any jurisdiction for this note.
Sources and status checked 2026-09-22
Pinealon — sizes and pricing